Additional file 1: Table S1. of Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients

Phisitt Vejakama (4218568)
Atiporn Ingsathit (4218571)
Gareth McKay (4632025)
Alexander Maxwell (4285855)
Mark McEvoy (276954)
John Attia (103776)
Ammarin Thakkinstian (840643)

Publication date

November 2017

DOI

10.6084/m9.figshare.5648785.v1

Abstract

Estimation of average treatment model for ESRD in diabetic patients. Table S2. Estimation of average treatment model for ESRD in non-diabetic patients (RTF 343Â kb

Extracted data

We use cookies to provide a better user experience.

Data Protection

Additional file 1: Table S1. of Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients

Phisitt Vejakama (4218568)
Atiporn Ingsathit (4218571)
Gareth McKay (4632025)
Alexander Maxwell (4285855)
Mark McEvoy (276954)
John Attia (103776)
Ammarin Thakkinstian (840643)

Open link

Publication date

November 2017

DOI

10.6084/m9.figshare.5648785.v1

Abstract

Estimation of average treatment model for ESRD in diabetic patients. Table S2. Estimation of average treatment model for ESRD in non-diabetic patients (RTF 343Â kb

Extracted data

Shusuke Hiragi (775758)
Hiroshi Tamura (371719)
Rei Goto (478222)
Tomohiro Kuroda (4389679)

November 2018

Figure S2. Implemented MSM-kf flowchart. Log-normal random numbers with reported mean and standard d...

Additional file 1 of The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors

Yi-Hsin Chan (843243)
Shao-Wei Chen (5714960)
Tze-Fan Chao (378407)
Yi-Wei Kao (6421310)
Chien-Ying Huang (6475646)
Pao-Hsien Chu (344527)

August 2021

Additional file 1: Table SI: Clinical characteristics of patients with type 2 diabetes mellitus (T2D...

Additional file 2 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 2: Figure S1. Risk for cardiovascular and kidney outcome in SGLT2i initiators compar...

Additional file 1: of Adherence to long-term use of renin-angiotensin II-aldosterone system inhibitors in children with chronic kidney disease

Chien-Ning Hsu (280485)
Shiou-Huei Huang (6385850)
You-Lin Tain (280484)

February 2019

Table S1. ICD 9 codes for disease conditions in the study. Table S2. Medications used to treat chron...

Additional file 2: of Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: a national cross-sectional study

Jo-Anne Manski-Nankervis (6157178)
Sharmala Thuraisingam (4540357)
Janet Sluggett (4764273)
Gary Kilov (4767870)
John Furler (3497654)
David OâNeal (6375131)
Alicia Jenkins (804281)

February 2019

Table S2. Prescription of non-insulin diabetes medications by eGFR for patients with average eGFR <6...

Additional file 1: Table S1. of Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Gemma Currie (2968041)
Alison Taylor (3581477)
Toshiro Fujita (360666)
Hiroshi Ohtsu (321603)
Morten Lindhardt (3581486)
Peter Rossing (135121)
Lene Boesby (197763)
Nicola Edwards (3581480)
Charles Ferro (512921)
Jonathan Townend (3581471)
Anton van den Meiracker (3581459)
Mohammad Saklayen (3581462)
Sonia Oveisi (3581474)
Alan Jardine (3581465)
Christian Delles (238556)
David Preiss (3581483)
Patrick Mark (3581468)

September 2016

Assessment of bias. Table S2. Baseline characteristics for individual study groups. Table S3. Compar...

Additional file 3 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 3: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...

Additional file 1: of Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

Hans Furuland (5269430)
Phil McEwan (688067)
Marc Evans (350030)
Cecilia Linde (5677514)
Daniel Ayoubkhani (5677517)
Ameet Bakhai (5677520)
Eirini Palaka (5677523)
Hayley Bennett (688069)
Lei Qin (27694)

August 2018

Table S1. Read and International Classification of Diseases (ICD-10) codes used to define heart fail...

Additional file 4 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 4: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...

Additional file 6 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 6: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...

Additional file 2: Figure S2. of Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort

Martin Busch (523317)
Jennifer Nadal (3479210)
Matthias Schmid (51150)
Katharina Paul (686395)
Stephanie Titze (825259)
Silvia Hübner (721164)
Anna Köttgen (3111024)
Ulla Schultheiss (3479207)
Seema Baid-Agrawal (3479201)
Johan Lorenzen (319945)
Georg Schlieper (721165)
Claudia Sommerer (3153246)
Vera Krane (135094)
Robert Hilge (3479204)
Jan Kielstein (3479198)
Florian Kronenberg (87557)
Christoph Wanner (156898)
Kai-Uwe Eckardt (186164)
Gunter Wolf (2679817)

June 2016

Association between hemoglobin and estimated glomerular filtration rate (eGFR) in 1759 patients havi...

Additional file 7 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 7: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...

Additional file 1: of Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

Claudia Sommerer (3153246)
Oliver Witzke (117125)
Frank Lehner (360876)
Wolfgang Arns (5467571)
Petra Reinke (373886)
Ute Eisenberger (4794330)
Bruno Vogt (541641)
Katharina Heller (567020)
Johannes Jacobi (5435624)
Markus Guba (784795)
Rolf Stahl (5467565)
Ingeborg Hauser (3512135)
Volker Kliem (5771747)
Rudolf WĂźthrich (5771783)
Anja MĂźhlfeld (5771786)
Barbara Suwelack (650393)
Michael Duerr (5771753)
Eva-Maria Paulus (5771756)
Martin Zeier (190503)
Martina Porstner (5467568)
Klemens Budde (4344541)

September 2018

Table S1. Inclusion and exclusion criteria. Table S2. Efficacy endpoints between randomization and m...

Additional file 1 of Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

Sok Cin Tye (10132332)
Niels Jongs (10686358)
Steven G. Coca (9396383)
Johan Sundström (232655)
Clare Arnott (2557705)
Bruce Neal (141486)
Vlado Perkovic (141532)
Kenneth W. Mahaffey (6390302)
Priya Vart (10686357)
Hiddo. J. L. Heerspink (13852925)

September 2022

Additional file 1: Box S1. Prediction of the effect ofcanagliflozin on the composite kidney risk for...

Additional file 5: Table S3. of Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort

Martin Busch (523317)
Jennifer Nadal (3479210)
Matthias Schmid (51150)
Katharina Paul (686395)
Stephanie Titze (825259)
Silvia Hübner (721164)
Anna Köttgen (3111024)
Ulla Schultheiss (3479207)
Seema Baid-Agrawal (3479201)
Johan Lorenzen (319945)
Georg Schlieper (721165)
Claudia Sommerer (3153246)
Vera Krane (135094)
Robert Hilge (3479204)
Jan Kielstein (3479198)
Florian Kronenberg (87557)
Christoph Wanner (156898)
Kai-Uwe Eckardt (186164)
Gunter Wolf (2679817)

June 2016

Correlates of median HbA1C levels >7.0 % (53 mmol/mol) including the most frequently used antidiabet...

Shusuke Hiragi (775758)
Hiroshi Tamura (371719)
Rei Goto (478222)
Tomohiro Kuroda (4389679)

November 2018

Figure S2. Implemented MSM-kf flowchart. Log-normal random numbers with reported mean and standard d...

Additional file 1 of The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors

Yi-Hsin Chan (843243)
Shao-Wei Chen (5714960)
Tze-Fan Chao (378407)
Yi-Wei Kao (6421310)
Chien-Ying Huang (6475646)
Pao-Hsien Chu (344527)

August 2021

Additional file 1: Table SI: Clinical characteristics of patients with type 2 diabetes mellitus (T2D...

Additional file 2 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 2: Figure S1. Risk for cardiovascular and kidney outcome in SGLT2i initiators compar...

Additional file 2: of Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: a national cross-sectional study

Jo-Anne Manski-Nankervis (6157178)
Sharmala Thuraisingam (4540357)
Janet Sluggett (4764273)
Gary Kilov (4767870)
John Furler (3497654)
David OâNeal (6375131)
Alicia Jenkins (804281)

February 2019

Table S2. Prescription of non-insulin diabetes medications by eGFR for patients with average eGFR <6...

Additional file 1: Table S1. of Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Gemma Currie (2968041)
Alison Taylor (3581477)
Toshiro Fujita (360666)
Hiroshi Ohtsu (321603)
Morten Lindhardt (3581486)
Peter Rossing (135121)
Lene Boesby (197763)
Nicola Edwards (3581480)
Charles Ferro (512921)
Jonathan Townend (3581471)
Anton van den Meiracker (3581459)
Mohammad Saklayen (3581462)
Sonia Oveisi (3581474)
Alan Jardine (3581465)
Christian Delles (238556)
David Preiss (3581483)
Patrick Mark (3581468)

September 2016

Assessment of bias. Table S2. Baseline characteristics for individual study groups. Table S3. Compar...

Additional file 3 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 3: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...

Additional file 1: of Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

Hans Furuland (5269430)
Phil McEwan (688067)
Marc Evans (350030)
Cecilia Linde (5677514)
Daniel Ayoubkhani (5677517)
Ameet Bakhai (5677520)
Eirini Palaka (5677523)
Hayley Bennett (688069)
Lei Qin (27694)

August 2018

Table S1. Read and International Classification of Diseases (ICD-10) codes used to define heart fail...

Additional file 4 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 4: Figure S2. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...

Additional file 6 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 6: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...

Martin Busch (523317)
Jennifer Nadal (3479210)
Matthias Schmid (51150)
Katharina Paul (686395)
Stephanie Titze (825259)
Silvia Hübner (721164)
Anna Köttgen (3111024)
Ulla Schultheiss (3479207)
Seema Baid-Agrawal (3479201)
Johan Lorenzen (319945)
Georg Schlieper (721165)
Claudia Sommerer (3153246)
Vera Krane (135094)
Robert Hilge (3479204)
Jan Kielstein (3479198)
Florian Kronenberg (87557)
Christoph Wanner (156898)
Kai-Uwe Eckardt (186164)
Gunter Wolf (2679817)

June 2016

Association between hemoglobin and estimated glomerular filtration rate (eGFR) in 1759 patients havi...

Additional file 7 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 7: Figure S4. Risk for cardiovascular and kidney outcomes in SGLT2i initiators compa...

Additional file 1: of Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

Claudia Sommerer (3153246)
Oliver Witzke (117125)
Frank Lehner (360876)
Wolfgang Arns (5467571)
Petra Reinke (373886)
Ute Eisenberger (4794330)
Bruno Vogt (541641)
Katharina Heller (567020)
Johannes Jacobi (5435624)
Markus Guba (784795)
Rolf Stahl (5467565)
Ingeborg Hauser (3512135)
Volker Kliem (5771747)
Rudolf WĂźthrich (5771783)
Anja MĂźhlfeld (5771786)
Barbara Suwelack (650393)
Michael Duerr (5771753)
Eva-Maria Paulus (5771756)
Martin Zeier (190503)
Martina Porstner (5467568)
Klemens Budde (4344541)

September 2018

Table S1. Inclusion and exclusion criteria. Table S2. Efficacy endpoints between randomization and m...

Additional file 1 of Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

Sok Cin Tye (10132332)
Niels Jongs (10686358)
Steven G. Coca (9396383)
Johan Sundström (232655)
Clare Arnott (2557705)
Bruce Neal (141486)
Vlado Perkovic (141532)
Kenneth W. Mahaffey (6390302)
Priya Vart (10686357)
Hiddo. J. L. Heerspink (13852925)

September 2022

Additional file 1: Box S1. Prediction of the effect ofcanagliflozin on the composite kidney risk for...

Martin Busch (523317)
Jennifer Nadal (3479210)
Matthias Schmid (51150)
Katharina Paul (686395)
Stephanie Titze (825259)
Silvia Hübner (721164)
Anna Köttgen (3111024)
Ulla Schultheiss (3479207)
Seema Baid-Agrawal (3479201)
Johan Lorenzen (319945)
Georg Schlieper (721165)
Claudia Sommerer (3153246)
Vera Krane (135094)
Robert Hilge (3479204)
Jan Kielstein (3479198)
Florian Kronenberg (87557)
Christoph Wanner (156898)
Kai-Uwe Eckardt (186164)
Gunter Wolf (2679817)

June 2016

Correlates of median HbA1C levels >7.0 % (53 mmol/mol) including the most frequently used antidiabet...

Shusuke Hiragi (775758)
Hiroshi Tamura (371719)
Rei Goto (478222)
Tomohiro Kuroda (4389679)

November 2018

Figure S2. Implemented MSM-kf flowchart. Log-normal random numbers with reported mean and standard d...

Additional file 1 of The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors

Yi-Hsin Chan (843243)
Shao-Wei Chen (5714960)
Tze-Fan Chao (378407)
Yi-Wei Kao (6421310)
Chien-Ying Huang (6475646)
Pao-Hsien Chu (344527)

August 2021

Additional file 1: Table SI: Clinical characteristics of patients with type 2 diabetes mellitus (T2D...

Additional file 2 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Meir Schechter (8637279)
Cheli Melzer-Cohen (6277318)
Aliza Rozenberg (10073015)
Ilan Yanuv (10073012)
Gabriel Chodick (362030)
Avraham Karasik (4530457)
Mikhail Kosiborod (6021260)
Ofri Mosenzon (11194789)

August 2021

Additional file 2: Figure S1. Risk for cardiovascular and kidney outcome in SGLT2i initiators compar...

Additional file 1: Table S1. of Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients

Abstract

Extracted data

Additional file 1: Table S1. of Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients

Abstract

Extracted data

Related items

Related items